Hydroxyurea medac 500 mg kapsel

DRUG2 trials

Sponsors

Akershus University Hospital, Karolinska University Hospital

Conditions

Acute myeloid leukemiaAdults (≥ 18 years of age) with relapsed or refractory acute myeloid leukemia (R/R AML)Chronic myelomonocyte leukemiaMyelodysplastic syndrome

Phase 1

FLAsH-IV-AML: A phase I/II multi-center study to assess the tolerability and efficacy of the addition of hydroxyurea to salvage treatment with fludarabine, ara-C, idarubicin and venetoclax for adults with relapsed or refractory acute myeloid leukemia

Not yet recruitingCTIS2026-526961-76-00

Karolinska University HospitalAdults (≥ 18 years of age) with relapsed or refractory acute myeloid leukemia (R/R AML)

Target: 26Updated: 2026-07-14

Phase 2

Precision therapy versus standard therapy in Acute Myeloid Leukaemia and Myelodysplastic syndrome in elderly (PALM) – a phase II randomized clinical trial

CompletedCTIS2023-509092-16-00

Akershus University HospitalAcute myeloid leukemia, Chronic myelomonocyte leukemia, Myelodysplastic syndrome

End: 2025-11-27Target: 33Updated: 2024-10-18